pioglitazone / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 296 Diseases   92 Trials   92 Trials   3449 News 
14 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
pioglitazone / Generic mfg.
NCT04976283: Effect of Oral Anti-diabetic Medication on Liver Fat in Subjects With Type II Diabetes and Non-alcoholic Fatty Liver

Recruiting
4
123
RoW
Pioglitazone, Zolid, Empagliflozin, Diampa, Pioglitazone + Empagliflozin, Zolid + Diampa
Getz Pharma
Diabetes Mellitus, Type 2, NASH - Nonalcoholic Steatohepatitis, NAFLD
05/23
11/23
EPIDOTE, NCT03499704: A Study to Evaluate the Effect of add-on Pioglitazone or Dapagliflozin in Participants With Type 2 Diabetes Mellitus Inadequately Controlled by DPP-4 Inhibitor and Metformin Therapy

Active, not recruiting
4
133
RoW
Pioglitazone + Alogliptin, SYR-322-4833, Alogliptin, Metformin, Dapagliflozin
Celltrion Pharm, Inc.
Diabetes Mellitus, Type 2
01/24
06/24
NCT06399835: Enavogliflozin vs. Pioglitazone on Glucose and Atherosclerosis

Recruiting
4
120
RoW
Enavogliflozin, Envlo Tab., Pioglitazone, Actos Tab.
Seoul National University Bundang Hospital, Daewoong Pharmaceutical Co. LTD.
Type 2 Diabetes
06/26
12/26
NCT04885712: A Study to Evaluate the Efficacy and Safety of Pioglitazone 15mg or 30mg Add-on in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin and Dapagliflozin

Completed
3
378
RoW
Metformin≥1000mg, BR3003D, Pioglitazone 15mg, BR3003A-1, Pioglitazone 30 mg, BR3003B-1, Pioglitazone 15mg Placebo, BR3003A-2, Pioglitazone 30mg Placebo, BR3003B-2, Dapagliflozin 10mg, BR3003C
Boryung Pharmaceutical Co., Ltd
Type2 Diabetes
09/22
03/23
PIEMONTE, NCT05028140: Efficacy and Safety of Piemonte Association in the Treatment of Type II Diabetes Mellitus

Not yet recruiting
3
480
NA
PIEMONTE, PIEMONTE PLACEBO, EMPAGLIFLOZIN, PLACEBO EMPAGLIFLOZIN, PIOGLITAZONE, PLACEBO PIOGLITAZONE
EMS
Type II Diabetes
03/26
09/26
2018-003817-16: A 52 weeks double blind, randomized and placebo controlled trial evaluating the effect of oral KIN001 150 mg plus pioglitazone 10 mg daily on injection frequency of Standard of Care in patients with diagnosed unilateral wet AMD undergoing a treat and extend regimen Eine 52-wöchige, doppelblinde, randomisierte und placebokontrollierte Studie zur Bewertung der Wirkung der täglichen oralen Gabe von KIN001 150 mg plus Pioglitazon 10 mg auf das Behandlungsintervall in der Standardtherapie bei Patienten mit diagnostizierter einseitiger feuchter altersbedingter Makuladegeneration (AMD)

Not yet recruiting
2
100
Europe
Pioglitazone, KIN001, Prolonged-release tablet, Film-coated tablet
Kinarus AG, Kinarus AG
wet age-related macular degeneration feuchte altersbedingte Makuladegeneration, wet age-related macular degeneration feuchte altersbedingte Makuladegeneration, Diseases [C] - Eye Diseases [C11]
 
 
2021-002367-21: Fettvävens sammansättning och dess koppling till typ 2 diabetes: En studie som jämför behandling med Empagliflozin, Pioglitazon och Semaglutide

Not yet recruiting
2
60
Europe
Film-coated tablet, Tablet, Jardiance 25 mg filmdragerade tabletter, Actos 15 mg tabletter, Actos 45 mg tabletter, Rybelsus 3 mg tabletter, Rybelsus 7 mg tabletter, Rybelsus 14 mg tabletter
Karolinska Universitetssjukhuset, Vetenskapsrådet, Diabetesfonden, SRP Diabetes
Diabetes typ 2, Diabetes typ 2, Diseases [C] - Nutritional and Metabolic Diseases [C18]
 
 
2020-005849-16: An 8-week double-blind, randomized, placebo-controlled, phase II study evaluating the effects of oral pamapimod 150 mg with pioglitazone 10 mg daily on COVID-19 development in hospitalized patients infected with SARS-CoV-2 (severe acute respiratory syndrome-coronavirus-2)

Not yet recruiting
2
432
Europe, RoW
Pioglitazone, KIN001, Prolonged-release tablet, Film-coated tablet
Kinarus AG, Kinarus AG
COVID-19 development in hospitalized patients infected with SARS-CoV-2, Hospitalized patients suffering from COVID-19, Diseases [C] - Virus Diseases [C02]
 
 
KIN-FAST, NCT05659459: The Trial (KIN001 For Accelerated Symptoms Termination) in Non Hospitalized Patients Infected With SARS-CoV-2

Suspended
2
400
Europe
KIN001, Combination Pamapimod 75mg with Pioglitazone 5mg, KIN001-Placebo
Kinarus AG
COVID-19
05/25
10/25
ENRICHPLUS, NCT05582707: Safety and Suitability of Supplementing Early MIP Surgery (MIPS) of ICH With Pioglitazone

Recruiting
2
20
US
Pioglitazone 15mg
University of Maryland, Baltimore, Nico Corporation
Intracerebral Haemorrhage, Intraventricular
07/25
07/26
NCT02592317: A Study to Evaluate the Effect of Multiple Doses of JNJ-56021927 on the Pharmacokinetics of Multiple Cytochrome P450 and Transporter Substrates in Participants With Castration-Resistant Prostate Cancer

Recruiting
1
20
Europe, RoW
JNJ 56021927, Drug Cocktail, Pioglitazone, Rosuvastatin
Aragon Pharmaceuticals, Inc.
Prostatic Neoplasms, Castration-Resistant
11/16
12/24
NCT03720366: A Study of Perpetrator Drug Interactions of Enasidenib in AML Patients

Completed
1
40
RoW
enasidenib, CC-90007, AG-221, Arm 1 probes, Arm 2 Probes, Arm 3 probes
Celgene
Leukemia, Myeloid, Acute
09/23
12/23
NCT02879409: HbA1c Variability in Type II Diabetes

Active, not recruiting
N/A
150
RoW
Metformin, Glucophage, Gliclazide, Diamicron, Diamicron MR, Sitagliptin, Januvia, Liraglutide, Victoza, Pioglitazone, Actos, Dapagliflozin, Forxiga, Farxiga, human insulin, novorapid, glargine
Weill Cornell Medical College in Qatar, Hamad Medical Corporation, Sidra Medical and Research Center, University of Hull
Diabetes Mellitus Type 2
10/23
10/24
IUAN, NCT00904046: Pathophysiology of Uric Acid Nephrolithiasis

Recruiting
N/A
60
US
Pioglitazone, Thiazolidinedione, Placebo
University of Texas Southwestern Medical Center, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Takeda Pharmaceuticals North America, Inc.
Uric Acid Kidney Stone Disease
11/24
12/24

Download Options